Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Ales Linhart

Prague, PR, CZ 
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Prague, PR, CZ 
OverviewLocationsClinical Research

Overview

Ales Linhart practices in Prague, Czech Republic. Mr. Linhart is rated as an Experienced expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Fabry Disease, Cardiomyopathy, Dilated Cardiomyopathy (DCM), Thrombectomy, and Cardiac Ablation.

His clinical research consists of co-authoring 231 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

Prague, PR, Czech Republic
Other Locations
Liberec, LI, Czech Republic
Stare Mesto, MO 11000, Czech Republic
Czech Republic
Brno, JM, Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: Cardiovascular Polypill, Treatment Prevention for Secondary CV
Study Phase: Phase 3
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
View 3 Less Clinical Trials

231 Total Publications

Cardiac Rhythm Conversions and the Outcome in Refractory Out-of-Hospital Cardiac Arrest: Extracorporeal Versus Conventional Resuscitation.
Cardiac Rhythm Conversions and the Outcome in Refractory Out-of-Hospital Cardiac Arrest: Extracorporeal Versus Conventional Resuscitation.
Journal: Critical care medicine
Published: July 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Linhart's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 43 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile